Rapport Therapeutics, Inc. - 8-K Filing
Rapport Therapeutics reports Q3 2026 net loss of $40.2 million and announces positive Phase 2 topline results for RAP-219 in bipolar mania. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $RAPP
Read the full article at SEC EDGAR
Part of the story IDEAYA Biosciences, Inc. - 8-K Filing (42 articles)